• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Report: More than 450 medicines in development for rare diseases

Report: More than 450 medicines in development for rare diseases

October 11, 2013
CenterWatch Staff

America’s biopharmaceutical research companies are developing 452 new medicines for rare diseases, including genetic disorders, neurological conditions, infectious diseases and autoimmune disorders, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA).

Biopharmaceutical research is entering an era with a growing understanding of the human genome. Scientific advances have given researchers new tools to explore rare diseases, which are often more complex than common diseases. According to the FDA, in the last five years, one third of all new drug approvals were for rare diseases.

Although a rare disease is defined as one that affects fewer than 200,000 people in the U.S., there are approximately 7,000 rare diseases and collectively they affect nearly 30 million people, or one in 10 Americans.

“Biopharmaceutical scientists are better equipped than ever before to bring new treatments—and hope—to patients battling one of the nearly 7,000 rare diseases. In order to capitalize on this scientific promise, we need to ensure that we have a policy and regulatory environment that helps foster this vital work,” said John J. Castellani, PhRMA president and CEO.

The 452 medicines and vaccines in development for rare diseases, all in human clinical trials or under review by the FDA, include 105 for cancer, 85 for genetic disorders, 65 for blood cancers and 32 for neurological disorders.

Rare diseases provide opportunities to study human physiology and biomedical science from unique perspectives, leading to insight into more common disorders. Advances in science and technology, such as personalized medicine, are creating new opportunities to improve and expand both research and development into rare diseases.

The development of medicines for rare diseases also poses unique challenges, such as recruitment of volunteers for clinical trials since the patient population with a specific rare disease is typically very small, geographically dispersed and often children.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing